JP2019526595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526595A5 JP2019526595A5 JP2019512763A JP2019512763A JP2019526595A5 JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5 JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5
- Authority
- JP
- Japan
- Prior art keywords
- cti
- antibody
- kinase
- delta inhibitor
- ubrituximab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385723P | 2016-09-09 | 2016-09-09 | |
| US62/385,723 | 2016-09-09 | ||
| PCT/US2017/050825 WO2018049263A1 (en) | 2016-09-09 | 2017-09-08 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526595A JP2019526595A (ja) | 2019-09-19 |
| JP2019526595A5 true JP2019526595A5 (https=) | 2020-10-15 |
Family
ID=59969229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512763A Pending JP2019526595A (ja) | 2016-09-09 | 2017-09-08 | 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190247399A1 (https=) |
| EP (1) | EP3509634A1 (https=) |
| JP (1) | JP2019526595A (https=) |
| KR (1) | KR20190068521A (https=) |
| CN (1) | CN110191720A (https=) |
| AU (1) | AU2017322501A1 (https=) |
| BR (1) | BR112019004185A2 (https=) |
| CA (1) | CA3035976A1 (https=) |
| CL (1) | CL2019000585A1 (https=) |
| EA (1) | EA201990374A1 (https=) |
| IL (1) | IL265194A (https=) |
| MX (1) | MX2019002728A (https=) |
| WO (1) | WO2018049263A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3478723T3 (fi) | 2016-06-29 | 2026-03-17 | Checkpoint Therapeutics Inc | Pd-l1-spesifisiä vasta-aineita ja niiden käyttömenetelmiä |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| WO2020191022A1 (en) * | 2019-03-18 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 9x |
| JP2022540466A (ja) * | 2019-07-15 | 2022-09-15 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | 非晶質ウムブラリシブモノトシレート |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2022171121A1 (zh) * | 2021-02-10 | 2022-08-18 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN118922208A (zh) * | 2022-02-28 | 2024-11-08 | 贾斯帕医疗公司 | 用于消耗患病造血干细胞的组合物和方法 |
| CN115141092A (zh) * | 2022-07-27 | 2022-10-04 | 诚达药业股份有限公司 | 一种抗淋巴瘤药物相关化合物的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1999004705A1 (en) | 1997-07-25 | 1999-02-04 | Tsui Ban C H | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| PH12012500901A1 (en) | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| EP2742953B1 (en) * | 2011-08-11 | 2021-09-22 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| SG11201503393SA (en) * | 2012-11-02 | 2015-06-29 | Tg Therapeutics Inc | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| ES2880999T3 (es) | 2014-05-27 | 2021-11-26 | Rhizen Pharmaceuticals S A | Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas |
| US20170239351A1 (en) * | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
-
2017
- 2017-09-08 CN CN201780066399.5A patent/CN110191720A/zh active Pending
- 2017-09-08 EP EP17772801.1A patent/EP3509634A1/en not_active Withdrawn
- 2017-09-08 WO PCT/US2017/050825 patent/WO2018049263A1/en not_active Ceased
- 2017-09-08 CA CA3035976A patent/CA3035976A1/en not_active Abandoned
- 2017-09-08 US US16/331,407 patent/US20190247399A1/en not_active Abandoned
- 2017-09-08 BR BR112019004185A patent/BR112019004185A2/pt not_active IP Right Cessation
- 2017-09-08 EA EA201990374A patent/EA201990374A1/ru unknown
- 2017-09-08 KR KR1020197008508A patent/KR20190068521A/ko not_active Ceased
- 2017-09-08 JP JP2019512763A patent/JP2019526595A/ja active Pending
- 2017-09-08 AU AU2017322501A patent/AU2017322501A1/en not_active Abandoned
- 2017-09-08 MX MX2019002728A patent/MX2019002728A/es unknown
-
2019
- 2019-03-06 IL IL265194A patent/IL265194A/en unknown
- 2019-03-07 CL CL2019000585A patent/CL2019000585A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526595A5 (https=) | ||
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2019506403A5 (https=) | ||
| KR102945599B1 (ko) | 암 치료를 위한 ch5126766과 조합된 vs-6063 | |
| US12447150B2 (en) | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
| RU2738934C2 (ru) | Способы лечения рака с использованием апилимода | |
| JP2019517485A5 (https=) | ||
| JP2020505433A5 (https=) | ||
| JP2017533912A5 (https=) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2012509889A5 (https=) | ||
| JP2011529968A5 (https=) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2017537927A5 (https=) | ||
| CN102753176A (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JPWO2020111018A5 (https=) | ||
| JP2017536408A5 (https=) | ||
| JP2019508433A (ja) | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 | |
| JP2019508476A5 (https=) | ||
| JP2018519300A5 (https=) | ||
| Iratni et al. | Sildenafil in combination therapy against cancer: a literature review | |
| JP2021522246A5 (https=) | ||
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 |